Jonathan Lu

Jonathan Lu is an accomplished Executive Director in Cardiovascular Gene Therapy at Alexion Pharmaceuticals, Inc., with a career spanning over two decades in the field of clinical medicine and translational research. Prior roles include Senior Director at SalioGen Therapeutics and Medical Director positions at Acceleron Pharma and Sarepta Therapeutics, where Jonathan led initiatives in pulmonary hypertension and developed strategic plans for medical affairs. Previously, a Medical Director at AstraZeneca, responsibilities included overseeing the development and execution of strategies for Ticagrelor. An academic background includes significant research at Columbia University focusing on genetic heart disease and training at prestigious institutions such as UCSF and the University of California, San Diego. Jonathan holds an MD PhD in Pharmacology from Vanderbilt University and a BS in Neuroscience from Brown University.